Serum levels of anti-corona virus specific -IgG and -IgM antibodies in COVID-19 patients at admission and at discharge
| dc.contributor.author | Ganiyu, Arinola | |
| dc.date.accessioned | 2021-03-15T10:38:00Z | |
| dc.date.available | 2021-03-15T10:38:00Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Introduction. Clear understanding of duration of antibody based protective immunity following natural infection with SARSCoV- 2 will give idea about the efficacy of proposed prophylactic vaccines against SARS-CoV-2, establishment of herd immunity and use of convalescent plasma. Aim. This study clarified the kinetics and magnitude of the initial antibody response against SARS-CoV-2 in a cohort of symptomatic COVID-19 patients from Ibadan, Nigeria. Material and methods. This study quantified immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 Spike (S) protein in 35 symptomatic COVID-19 patients at admission and at discharge using ELISA. Results. CovIgG was positive in none (0)% and 20% of COVID-19 patients at admission and at discharge respectively while CovIgM was positive in 54% and 69% of COVID-19 patients at admission and at discharged respectively. The level of CovIgG was significantly higher in COVID-19 patients at discharge compared with the level at admission while the level of CovIgM was insignificantly reduced in COVID-19 patients at discharge compared with the level at admission. Conclusion. The data indicates increased anti-SARS-COV-2 IgG Spike antibody in symptomatic COVID-19 at discharge, thus providing basis for antibody-based therapies to treat COVID-19 patients. | pl_PL.UTF-8 |
| dc.identifier.citation | European Journal of Clinical and Experimental Medicine T. 19, z. 1 (2021), s. 5–9 | pl_PL.UTF-8 |
| dc.identifier.doi | 10.15584/ejcem.2021.1.1 | |
| dc.identifier.eissn | 2544-1361 | |
| dc.identifier.issn | 2544-2406 | |
| dc.identifier.uri | http://repozytorium.ur.edu.pl/handle/item/6116 | |
| dc.language.iso | eng | pl_PL.UTF-8 |
| dc.publisher | Wydawnictwo Uniwersytetu Rzeszowskiego | pl_PL.UTF-8 |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject | anti-SARS-CoV-2 specific antibodies | pl_PL.UTF-8 |
| dc.subject | convalescence plasma | pl_PL.UTF-8 |
| dc.subject | COVID-19 | pl_PL.UTF-8 |
| dc.subject | spike protein | pl_PL.UTF-8 |
| dc.subject | vaccine | pl_PL.UTF-8 |
| dc.title | Serum levels of anti-corona virus specific -IgG and -IgM antibodies in COVID-19 patients at admission and at discharge | pl_PL.UTF-8 |
| dc.type | article | pl_PL.UTF-8 |